Trial · NCT06956885
Registered outcomes77
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
61 to 77 of 77
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Consumption of other drugs | At 24 months | Colchicine, NSAIDs, steroids using a patient self-reported notebook |
| Secondary | Consumption of other drugs | At 30 months | Colchicine, NSAIDs, steroids using a patient self-reported notebook |
| Secondary | Consumption of other drugs | At 36 months | Colchicine, NSAIDs, steroids using a patient self-reported notebook |
| Secondary | Incidence of adverse events and serious adverse events | At 6 months | According to CTCAE v5.0 classification (Common Terminology Criteria for Adverse Events) |
| Secondary | Incidence of adverse events and serious adverse events | At 12 months | According to CTCAE v5.0 classification (Common Terminology Criteria for Adverse Events) |
| Secondary | Incidence of adverse events and serious adverse events | At 18 months | According to CTCAE v5.0 classification (Common Terminology Criteria for Adverse Events) |
| Secondary | Incidence of adverse events and serious adverse events | At 24 months | According to CTCAE v5.0 classification (Common Terminology Criteria for Adverse Events) |
| Secondary | Incidence of adverse events and serious adverse events | At 30 months | According to CTCAE v5.0 classification (Common Terminology Criteria for Adverse Events) |
| Secondary | Incidence of adverse events and serious adverse events | At 36 months | According to CTCAE v5.0 classification (Common Terminology Criteria for Adverse Events) |
| Secondary | Adherence to ULT | At 6 months | Assessed by a questionnaire |
| Secondary | Adherence to ULT | At 12 months | Assessed by a questionnaire |
| Secondary | Adherence to ULT | At 18 months | Assessed by a questionnaire |
| Secondary | Adherence to ULT | At 24 months | Assessed by a questionnaire |
| Secondary | Adherence to ULT | At 30 months | Assessed by a questionnaire |
| Secondary | Adherence to ULT | At 36 months | Assessed by a questionnaire |
| Secondary | Incremental Cost effectiveness ratios estimating cost per QALY gained | Up to 36 months | |
| Secondary | Incremental Cost effectiveness ratios estimating cost per flare avoided. | Up to 36 months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06956885/registered?page=4